Anticancer evaluation of new organometallic ruthenium(II) flavone complexes

被引：16

作者：

Khater, Mai ^{[1
,2
]}

Brazier, John A. A. ^{[1
]}

Greco, Francesca ^{[1
]}

Osborn, Helen M. I. ^{[1
]}

机构：

[1] Univ Reading, Sch Pharm, Reading RG6 6AD, England

[2] Natl Res Ctr, Therapeut Chem Dept, Pharmaceut & Drug Ind Res Div, Cairo, Egypt

来源：

RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 02期

关键词：

PHASE-I; ANGIOGENESIS; CANCER; DNA; DERIVATIVES; PROMOTERS; INVASION; BINDING;

D O I：

10.1039/d2md00304j

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeting multiple malignancy features such as angiogenesis, proliferation and metastasis with one molecule is an effective strategy in developing potent anticancer agents. Ruthenium metal complexation to bioactive scaffolds is reported to enhance their biological activities. Herein, we evaluate the impact of Ru chelation on the pharmacological activities of two bioactive flavones (1 and 2) as anticancer candidates. The novel Ru complexes (1Ru and 2Ru) caused a loss of their parent molecules' antiangiogenic activities in an endothelial cell tube formation assay. 1Ru enhanced the antiproliferative and antimigratory activities of its 4-oxoflavone 1 on MCF-7 breast cancer cells (IC50 = 66.15 +/- 5 mu M and 50% migration inhibition, p < 0.01 at 1 mu M). 2Ru diminished 4-thioflavone's (2) cytotoxic activity on MCF-7 and MDA-MB-231 yet significantly enhanced 2's migration inhibition (p < 0.05) particularly on the MDA-MB-231 cell line. The test derivatives also showed non-intercalative interaction with VEGF and c-myc i-motif DNA sequences.

引用

页码：253 / 267

页数：15

共 58 条

[1] Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy [J].

Abid, Mohammad ;

Shamsi, Farheen ;

Azam, Amir .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (10) :772-786

[2] i-Motif DNA: structural features and significance to cell biology [J].

Abou Assi, Hala ;

Garavis, Miguel ;

Gonzalez, Carlos ;

Damha, Masad J. .

NUCLEIC ACIDS RESEARCH, 2018, 46 (16) :8038-8056

[3] Janus PEG-Based Dendrimers for Use in Combination Therapy: Controlled Multi-Drug Loading and Sequential Release [J].

Acton, Aaron L. ;

Fante, Cristina ;

Flatley, Brian ;

Burattini, Stefano ;

Hamley, Ian W. ;

Wang, Zuowei ;

Greco, Francesca ;

Hayes, Wayne .

BIOMACROMOLECULES, 2013, 14 (02) :564-574

[4]

[Anonymous], END CELL TUB FORM AS

[5]

[Anonymous], ANG AN IMAGEJ GILL C

[6] A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids [J].

Beekmann, Karsten ;

Actis-Goretta, Lucas ;

van Bladeren, Peter J. ;

Dionisi, Fabiola ;

Destaillats, Frederic ;

Rietjens, Ivonne M. C. M. .

FOOD & FUNCTION, 2012, 3 (10) :1008-1018

[7] Fundamental aspects of the nucleic acid i-motif structures [J].

Benabou, S. ;

Avino, A. ;

Eritja, R. ;

Gonzalez, C. ;

Gargallo, R. .

RSC ADVANCES, 2014, 4 (51) :26956-26980

[8] Use of UV-Vis Spectrometry to Gain Information on the Mode of Binding of Small Molecules to DNAs and RNAs [J].

Biver, T. .

APPLIED SPECTROSCOPY REVIEWS, 2012, 47 (04) :272-325

[9] I-Motif formation in gene promoters: unusually stable formation in sequences complementary to known G-quadruplexes [J].

Brazier, John A. ;

Shah, Arti ;

Brown, Geoffrey D. .

CHEMICAL COMMUNICATIONS, 2012, 48 (87) :10739-10741

[10] The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure [J].

Brown, Susie L. ;

Kendrick, Samantha .

PHARMACEUTICALS, 2021, 14 (02) :1-25

← 1 2 3 4 5 6 →